Table 1.
Clinical characteristics of cohort
| Gleason grade group | T-stage | Number of patients | Age (mean±SD) |
PSA (ng/mL) |
Neoadjuvant ADT | Relapse |
| 2 | 1c | 4 | 59.3±7.9 | 6.1±1.6 | 0/4 | |
| 2a | 2 | 70.5±3.5 | 7.7±4.6 | 0/2 | ||
| 2b | 2 | 70.0±1.4 | 8.8±1.9 | 0/2 | ||
| Total | 8 | 64.8±8.0 | 7.1±2.5 | 0/8 (0%) | ||
| 3 | 1c | 5 | 63.0±4.5 | 21.6±32.8 | 1/5 | 1 |
| 2b | 3 | 65.3±4.2 | 12.1±6.8 | 0/3 | ||
| 2c | 1 | 70.0 | 11.3 | 1/1 | ||
| 3a | 1 | 67.0 | 11.2 | 0/1 | 1 | |
| 3b | 1 | 57.0 | 80.0 | 1/1 | ||
| Total | 11 | 64.1±4.7 | 22.4±28.8 | 3/11 (27%) | ||
| 4 | 1c | 1 | 76.0 | 27.7 | 1/1 | |
| 2a | 1 | 70.0 | 6.1 | 0/1 | ||
| Total | 2 | 73.0±4.2 | 16.9±15.3 | 1/2 (50%) | ||
| 5 | 2a | 1 | 66.0 | 6.4 | 0/1 | |
| 2b | 1 | 73.0 | 7.2 | 1/1 | ||
| 3b | 1 | 67.0 | 10.3 | 1/1 | 1 | |
| Total | 3 | 68.7±3.8 | 8.0±2.1 | 2/3 (67%) | ||
| 24 | 65.6±6.2 | 15.1±20.7 | 6/24 (25%) | 3/24 (12.5%) |
ADT, androgen deprivation therapy.